2,439 Stryker Corporation $SYK Shares Sold by Baskin Financial Services Inc.

Baskin Financial Services Inc. decreased its position in Stryker Corporation (NYSE:SYK) by 2.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 110,407 shares of the medical technology company’s stock after selling 2,439 shares during the quarter. Stryker comprises approximately 2.5% of Baskin Financial Services Inc.’s investment portfolio, making the stock its 21st biggest position. Baskin Financial Services Inc.’s holdings in Stryker were worth $30,405,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in SYK. State Street Corp boosted its stake in Stryker by 1.2% in the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock valued at $4,903,772,000 after purchasing an additional 183,400 shares during the period. Wellington Management Group LLP increased its position in Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after buying an additional 45,478 shares during the period. Bank of America Corp DE bought a new position in Stryker during the 2nd quarter worth $1,404,284,000. Royal Bank of Canada lifted its holdings in shares of Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after buying an additional 199,863 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Stryker by 21.8% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock worth $846,723,000 after buying an additional 481,175 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of a number of recent research reports. Sanford C. Bernstein reissued a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. Stifel Nicolaus lowered their price target on shares of Stryker from $360.00 to $330.00 and set a “buy” rating on the stock in a research report on Wednesday, September 30th. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Wolfe Research cut shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Finally, Evercore set a $350.00 price objective on shares of Stryker in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $369.00.

Stryker Price Performance

Stryker stock traded up $3.94 during mid-day trading on Monday, reaching $298.60. 1,218,776 shares of the company were exchanged, compared to its average volume of 2,443,594. The firm has a market cap of $114.54 billion, a PE ratio of 30.96, a PEG ratio of 1.87 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a fifty day simple moving average of $299.31 and a 200-day simple moving average of $312.76. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $392.55.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts expect that Stryker Corporation will post 14.93 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Insider Buying and Selling

In related news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 351,267 shares of company stock valued at $118,197,701 over the last quarter. 4.60% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.